Table 1 Detailed characteristics of included studies comparing liberal glucose control with other glycemic target control groups in critically ill patients
From: Effect of liberal glucose control on critically ill patients: a systematic review and meta-analysis
No. | First Author | Publication Year | Country | Study Design | Diabetic n(%) | Sample size | Sex (male/ female) | Age | Blood glucose level at ICU admission, mmol/L | Blood glucose values starting with insulin | Treatment | Clinical scores | Follow-up (days) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Experimental group Target glucose (mg/dL) | Control group Target glucose (mg/dL) | APACHE II during first 24Â h | TISS-28 during first 24Â h | APACHE II during second 24Â h | TISS-28 during second 24Â h | APACHE III score | Baseline APACHE II score | ||||||||||||
1 | Vanhorebeek et al. | 2006 | Belgium | RCT | E: 25 (10%) C: 21 (10%) | E: 243 C: 208 | E: 164/79 C: 144/64 | E: 61 ± 16 C: 62 ± 15 | E: 147.6 ± 55.6 C: 144.2 ± 52.9 | E:>215 mg/dl C: NA | 180–200 mg/dl | 80–110 mg/dl | E: 12 (8, 15) C: 11 (7, 15) | E: 39 (33, 45) C: 40 (35, 45) | NA | NA | NA | NA | NA |
2 | Luethi et al. | 2019 | Australia | Non-RCT | E: 189(94.5%) C: 189 (94.5%) | E: 200 C: 200 | E: 154/46 C: 130/70 | E: 66(59,74) C: 67(60,75) | E: 8.6(6.7,11.0) C: 8.6(7.0,12.0) | E: >252 mg/dl C: >180 mg/dl | 180–200 mg/dl | 108–180 mg/dl | NA | NA | NA | NA | E:61 (46, 81) C: 56 (43, 72) | NA | NA |
3 | van den Berghe et al. | 2001 | Belgium | RCT | E: 103(13) C: 101(13) | E: 783 C: 765 | E: 557/226 C: 544/221 | E: 62.2 ± 13.9 C: 63.4 ± 13.6 | NA | E:>215 mg/dl C:>110 mg/dl | 180–200 mg/dl | 80–110 mg/dl | E: 9 (7, 13) C: 9 (7, 13) | E: 43 (36, 47) C: 43 (37, 46) | E: 9 (6, 13) C: 9 (6, 13) | E: 38 (32, 44) C: 38 (31, 43) | NA | NA | NA |
4 | van den Berghe et al. | 2006 | Belgium | RCT | E: 97(16.0) C: 106(17.8) | E: 605 C: 595 | E: 382/223 C: 356/239 | E: 64 ± 16 C: 63 ± 16 | E: 162 ± 70 C: 162 ± 71 | E:>215 mg/dl C:>110 mg/dl | 180–200 mg/dl | 80–110 mg/dl | NA | NA | NA | NA | NA | E: 23 ± 9 C: 23 ± 10 | 90 |
E: 58(15.2) C: 59(15.3) | E: 381 C: 386 | E: 243/138 C: 224/162 | E: 64 ± 16 C: 62 ± 16 | E: 164 ± 68 C: 163 ± 67 | NA | NA | NA | NA | NA | E: 24 ± 9 C: 24 ± 10 | |||||||||
5 | Luethi et al. | 2018 | Australia | Non-RCT | E: 350(100%) C: 350 (100%) | E: 350 C: 350 | E: 256/94 C: 232/118 | E: 67(59,75) C: 68(60,75) | E: 8.6(6.7,11.0) C: 8.6(7.0,12.0) | E: >252 mg/dl C: >180 mg/dl | 180-252 mg/dl | 108–180 mg/dl | NA | NA | NA | NA | E:60 (45, 75) C: 56 (43, 70) | NA | 30 |
6 | Di Muzio et al. | 2016 | Australia | Non-RCT | E: 40(100%) C: 40 (100%) | E: 40 C: 40 | E: 28/12 C: 25/15 | E: 69(61,73) C: 68(60,77) | NA | NA | 180-252 mg/dl | 108–180 mg/dl | NA | NA | NA | NA | E:52 (40, 77) C:59 (46, 72) | NA | NA |
7 | Kar et al. | 2016 | Australia | Non-RCT | E: 31(100%) C: 52 (100%) | E: 31 C: 52 | E: 18/13 C: 30/22 | E: 62.8 ± 11.5 C: 63.7 ± 14.5 | NA | E: >252 mg/dl C: >180 mg/dl | 180-252 mg/dl | 108–180 mg/dl | NA | NA | NA | NA | E: 72.9 ± 22.6 C: 74.7 ± 26.9 | E: 19.9 ± 6.4 C: 20.4 ± 7.1 | 90 |
8 | Poole et al. | 2022 | Australia | RCT | E: 210(100%) C: 209(100%) | E: 210 C:209 | E: 138/72 C: 136/73 | E: 67(58,75) C: 66(58,73) | NA | E: >252 mg/dl C: >180 mg/dl | 180-252 mg/dl | 108–180 mg/dl | NA | NA | NA | NA | E:74 (55, 95) C:71 (58, 93) | E:20 (16, 26) C: 20 (16, 26) | 90 |
9 | Gunst et al. | 2023 | Belgium | RCT | E: 955(20.7%) C: 933(20.2%) | E: 4622 C:4608 | E: 2902/1720 C: 2930/1678 | E: 67(56,75) C: 67(57,75) | NA | E:>215 mg/dl C:>180 mg/dl | 180-215 mg/dl | 80–110 mg/dl | NA | NA | NA | NA | NA | E:21 (15, 30) C:21 (15, 30) | 90 |